nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—Plasmacytoma—Pamidronate—osteoporosis	0.0226	0.0592	CcSEcCtD
Ruxolitinib—Plasma cell myeloma—Pamidronate—osteoporosis	0.0226	0.0592	CcSEcCtD
Ruxolitinib—Plasma cell myeloma—Zoledronate—osteoporosis	0.0206	0.054	CcSEcCtD
Ruxolitinib—Plasmacytoma—Zoledronate—osteoporosis	0.0206	0.054	CcSEcCtD
Ruxolitinib—Prostate cancer—Zoledronate—osteoporosis	0.0124	0.0325	CcSEcCtD
Ruxolitinib—RET—parathyroid gland—osteoporosis	0.0117	0.162	CbGeAlD
Ruxolitinib—PLK1—uterus—osteoporosis	0.00487	0.0677	CbGeAlD
Ruxolitinib—Night sweats—Zoledronate—osteoporosis	0.0044	0.0115	CcSEcCtD
Ruxolitinib—Bone pain—Etidronic acid—osteoporosis	0.00418	0.011	CcSEcCtD
Ruxolitinib—Herpes zoster—Risedronate—osteoporosis	0.00364	0.00953	CcSEcCtD
Ruxolitinib—Hypercholesterolaemia—Ibandronate—osteoporosis	0.00351	0.0092	CcSEcCtD
Ruxolitinib—Bone pain—Ibandronate—osteoporosis	0.00347	0.00909	CcSEcCtD
Ruxolitinib—Herpes zoster—Pamidronate—osteoporosis	0.00346	0.00906	CcSEcCtD
Ruxolitinib—Hypercholesterolaemia—Calcitriol—osteoporosis	0.00344	0.00901	CcSEcCtD
Ruxolitinib—CYP3A4—Estropipate—osteoporosis	0.00342	0.181	CbGbCtD
Ruxolitinib—CYP3A4—Calcitriol—osteoporosis	0.00342	0.181	CbGbCtD
Ruxolitinib—Bone pain—Calcitriol—osteoporosis	0.00339	0.0089	CcSEcCtD
Ruxolitinib—Night sweats—Estradiol—osteoporosis	0.00339	0.00889	CcSEcCtD
Ruxolitinib—Haematuria—Calcium Acetate—osteoporosis	0.00325	0.00853	CcSEcCtD
Ruxolitinib—Contusion—Risedronate—osteoporosis	0.00314	0.00822	CcSEcCtD
Ruxolitinib—JAK1—uterus—osteoporosis	0.00312	0.0433	CbGeAlD
Ruxolitinib—DCLK1—uterus—osteoporosis	0.00312	0.0433	CbGeAlD
Ruxolitinib—Weight decreased—Ergocalciferol—osteoporosis	0.00306	0.00801	CcSEcCtD
Ruxolitinib—Hypercholesterolaemia—Risedronate—osteoporosis	0.00289	0.00758	CcSEcCtD
Ruxolitinib—Bone pain—Risedronate—osteoporosis	0.00286	0.00749	CcSEcCtD
Ruxolitinib—DAPK3—uterus—osteoporosis	0.0028	0.0389	CbGeAlD
Ruxolitinib—CYP3A4—Ergocalciferol—osteoporosis	0.00274	0.145	CbGbCtD
Ruxolitinib—Bone pain—Pamidronate—osteoporosis	0.00272	0.00712	CcSEcCtD
Ruxolitinib—JAK1—bone marrow—osteoporosis	0.00265	0.0368	CbGeAlD
Ruxolitinib—PLK4—bone marrow—osteoporosis	0.00263	0.0366	CbGeAlD
Ruxolitinib—BMPR2—uterus—osteoporosis	0.00261	0.0363	CbGeAlD
Ruxolitinib—DAPK2—bone marrow—osteoporosis	0.00253	0.0351	CbGeAlD
Ruxolitinib—Bone pain—Zoledronate—osteoporosis	0.00248	0.0065	CcSEcCtD
Ruxolitinib—Herpes zoster—Estradiol—osteoporosis	0.00243	0.00638	CcSEcCtD
Ruxolitinib—Pancytopenia—Etidronic acid—osteoporosis	0.00239	0.00625	CcSEcCtD
Ruxolitinib—PLK1—Calcipotriol—Calcitriol—osteoporosis	0.00237	0.24	CbGdCrCtD
Ruxolitinib—PLK1—Calcipotriol—Ergocalciferol—osteoporosis	0.00237	0.24	CbGdCrCtD
Ruxolitinib—CLK2—bone marrow—osteoporosis	0.00235	0.0327	CbGeAlD
Ruxolitinib—CAMK2G—uterus—osteoporosis	0.00233	0.0324	CbGeAlD
Ruxolitinib—CYP3A4—Raloxifene—osteoporosis	0.00228	0.121	CbGbCtD
Ruxolitinib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.00221	0.117	CbGbCtD
Ruxolitinib—Anaemia—Ergocalciferol—osteoporosis	0.00218	0.0057	CcSEcCtD
Ruxolitinib—MAP3K2—uterus—osteoporosis	0.00212	0.0295	CbGeAlD
Ruxolitinib—NUAK2—bone marrow—osteoporosis	0.00212	0.0294	CbGeAlD
Ruxolitinib—MAP3K7—uterus—osteoporosis	0.0021	0.0292	CbGeAlD
Ruxolitinib—Contusion—Estradiol—osteoporosis	0.0021	0.0055	CcSEcCtD
Ruxolitinib—TYK2—uterus—osteoporosis	0.00206	0.0287	CbGeAlD
Ruxolitinib—MKNK2—uterus—osteoporosis	0.00204	0.0283	CbGeAlD
Ruxolitinib—PLK1—Calcipotriol—Cholecalciferol—osteoporosis	0.00201	0.204	CbGdCrCtD
Ruxolitinib—CAMK2G—bone marrow—osteoporosis	0.00198	0.0275	CbGeAlD
Ruxolitinib—BMP2K—bone marrow—osteoporosis	0.00198	0.0275	CbGeAlD
Ruxolitinib—Weight increased—Estropipate—osteoporosis	0.00198	0.00518	CcSEcCtD
Ruxolitinib—LRRK2—bone marrow—osteoporosis	0.00196	0.0273	CbGeAlD
Ruxolitinib—Infestation—Estropipate—osteoporosis	0.00194	0.00508	CcSEcCtD
Ruxolitinib—Infestation NOS—Estropipate—osteoporosis	0.00194	0.00508	CcSEcCtD
Ruxolitinib—Weight increased—Raloxifene—osteoporosis	0.00192	0.00502	CcSEcCtD
Ruxolitinib—Bone pain—Estradiol—osteoporosis	0.00191	0.00501	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Pamidronate—osteoporosis	0.00189	0.00495	CcSEcCtD
Ruxolitinib—Weight decreased—Ibandronate—osteoporosis	0.00189	0.00494	CcSEcCtD
Ruxolitinib—Infestation—Ibandronate—osteoporosis	0.00186	0.00487	CcSEcCtD
Ruxolitinib—Infestation NOS—Ibandronate—osteoporosis	0.00186	0.00487	CcSEcCtD
Ruxolitinib—Weight decreased—Calcitriol—osteoporosis	0.00185	0.00484	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Estropipate—osteoporosis	0.00183	0.0048	CcSEcCtD
Ruxolitinib—Urinary tract infection—Raloxifene—osteoporosis	0.00182	0.00478	CcSEcCtD
Ruxolitinib—Urinary tract infection—Ibandronate—osteoporosis	0.00181	0.00473	CcSEcCtD
Ruxolitinib—MAP3K2—bone marrow—osteoporosis	0.0018	0.025	CbGeAlD
Ruxolitinib—MAP3K7—bone marrow—osteoporosis	0.00178	0.0248	CbGeAlD
Ruxolitinib—Urinary tract infection—Calcitriol—osteoporosis	0.00177	0.00463	CcSEcCtD
Ruxolitinib—CYP3A4—Cholecalciferol—osteoporosis	0.00176	0.0934	CbGbCtD
Ruxolitinib—Hepatobiliary disease—Ibandronate—osteoporosis	0.00176	0.00461	CcSEcCtD
Ruxolitinib—TYK2—bone marrow—osteoporosis	0.00175	0.0243	CbGeAlD
Ruxolitinib—IRAK1—bone marrow—osteoporosis	0.00173	0.024	CbGeAlD
Ruxolitinib—MKNK2—bone marrow—osteoporosis	0.00173	0.024	CbGeAlD
Ruxolitinib—Flatulence—Etidronic acid—osteoporosis	0.00173	0.00452	CcSEcCtD
Ruxolitinib—Haemoglobin—Alendronate—osteoporosis	0.00172	0.00451	CcSEcCtD
Ruxolitinib—Haemorrhage—Alendronate—osteoporosis	0.00171	0.00449	CcSEcCtD
Ruxolitinib—Haemoglobin—Ibandronate—osteoporosis	0.00168	0.00439	CcSEcCtD
Ruxolitinib—Haemorrhage—Ibandronate—osteoporosis	0.00167	0.00437	CcSEcCtD
Ruxolitinib—TAOK3—uterus—osteoporosis	0.00165	0.0229	CbGeAlD
Ruxolitinib—Haemoglobin—Calcitriol—osteoporosis	0.00164	0.0043	CcSEcCtD
Ruxolitinib—Haemorrhage—Calcitriol—osteoporosis	0.00163	0.00428	CcSEcCtD
Ruxolitinib—CYP3A4—Conjugated Estrogens—osteoporosis	0.00162	0.0858	CbGbCtD
Ruxolitinib—Anaemia—Etidronic acid—osteoporosis	0.00162	0.00424	CcSEcCtD
Ruxolitinib—Weight increased—Ethinyl Estradiol—osteoporosis	0.0016	0.0042	CcSEcCtD
Ruxolitinib—Weight decreased—Ethinyl Estradiol—osteoporosis	0.00159	0.00418	CcSEcCtD
Ruxolitinib—JAK2—bone marrow—osteoporosis	0.00159	0.0221	CbGeAlD
Ruxolitinib—Infestation NOS—Ethinyl Estradiol—osteoporosis	0.00157	0.00412	CcSEcCtD
Ruxolitinib—Infestation—Ethinyl Estradiol—osteoporosis	0.00157	0.00412	CcSEcCtD
Ruxolitinib—PLK1—Fulvestrant—Estradiol—osteoporosis	0.00156	0.158	CbGdCrCtD
Ruxolitinib—PLK4—Fulvestrant—Estradiol—osteoporosis	0.00156	0.158	CbGdCrCtD
Ruxolitinib—Asthenia—Calcium Acetate—osteoporosis	0.00156	0.00409	CcSEcCtD
Ruxolitinib—Pruritus—Calcium Acetate—osteoporosis	0.00154	0.00403	CcSEcCtD
Ruxolitinib—MAP3K3—bone marrow—osteoporosis	0.00153	0.0213	CbGeAlD
Ruxolitinib—Infestation NOS—Risedronate—osteoporosis	0.00153	0.00401	CcSEcCtD
Ruxolitinib—Infestation—Risedronate—osteoporosis	0.00153	0.00401	CcSEcCtD
Ruxolitinib—Neutropenia—Pamidronate—osteoporosis	0.00153	0.004	CcSEcCtD
Ruxolitinib—Urinary tract infection—Ethinyl Estradiol—osteoporosis	0.00153	0.004	CcSEcCtD
Ruxolitinib—Malnutrition—Estropipate—osteoporosis	0.00151	0.00397	CcSEcCtD
Ruxolitinib—Flatulence—Estropipate—osteoporosis	0.00149	0.00391	CcSEcCtD
Ruxolitinib—Urinary tract infection—Risedronate—osteoporosis	0.00149	0.0039	CcSEcCtD
Ruxolitinib—Flatulence—Alendronate—osteoporosis	0.00147	0.00385	CcSEcCtD
Ruxolitinib—Infestation—Pamidronate—osteoporosis	0.00146	0.00382	CcSEcCtD
Ruxolitinib—Infestation NOS—Pamidronate—osteoporosis	0.00146	0.00382	CcSEcCtD
Ruxolitinib—Malnutrition—Ibandronate—osteoporosis	0.00145	0.00381	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Risedronate—osteoporosis	0.00145	0.0038	CcSEcCtD
Ruxolitinib—Flatulence—Raloxifene—osteoporosis	0.00145	0.00379	CcSEcCtD
Ruxolitinib—Dizziness—Calcium Acetate—osteoporosis	0.00144	0.00377	CcSEcCtD
Ruxolitinib—Flatulence—Ibandronate—osteoporosis	0.00143	0.00375	CcSEcCtD
Ruxolitinib—CYP3A4—Estradiol—osteoporosis	0.00142	0.0753	CbGbCtD
Ruxolitinib—Infection—Etidronic acid—osteoporosis	0.00142	0.00372	CcSEcCtD
Ruxolitinib—Haemoglobin—Ethinyl Estradiol—osteoporosis	0.00142	0.00371	CcSEcCtD
Ruxolitinib—Pancytopenia—Zoledronate—osteoporosis	0.00142	0.00371	CcSEcCtD
Ruxolitinib—Urinary tract infection—Pamidronate—osteoporosis	0.00142	0.00371	CcSEcCtD
Ruxolitinib—Haemorrhage—Ethinyl Estradiol—osteoporosis	0.00141	0.0037	CcSEcCtD
Ruxolitinib—TAOK3—bone marrow—osteoporosis	0.0014	0.0194	CbGeAlD
Ruxolitinib—Neutropenia—Zoledronate—osteoporosis	0.00139	0.00365	CcSEcCtD
Ruxolitinib—Haematuria—Pamidronate—osteoporosis	0.00139	0.00364	CcSEcCtD
Ruxolitinib—Haemoglobin—Risedronate—osteoporosis	0.00138	0.00362	CcSEcCtD
Ruxolitinib—Asthenia—Ergocalciferol—osteoporosis	0.00138	0.00361	CcSEcCtD
Ruxolitinib—Anaemia—Alendronate—osteoporosis	0.00138	0.00361	CcSEcCtD
Ruxolitinib—Haemorrhage—Risedronate—osteoporosis	0.00137	0.0036	CcSEcCtD
Ruxolitinib—Weight increased—Zoledronate—osteoporosis	0.00136	0.00356	CcSEcCtD
Ruxolitinib—Weight decreased—Zoledronate—osteoporosis	0.00135	0.00354	CcSEcCtD
Ruxolitinib—Anaemia—Ibandronate—osteoporosis	0.00134	0.00352	CcSEcCtD
Ruxolitinib—Infestation NOS—Zoledronate—osteoporosis	0.00133	0.00348	CcSEcCtD
Ruxolitinib—Infestation—Zoledronate—osteoporosis	0.00133	0.00348	CcSEcCtD
Ruxolitinib—Haemoglobin—Pamidronate—osteoporosis	0.00131	0.00344	CcSEcCtD
Ruxolitinib—Weight increased—Conjugated Estrogens—osteoporosis	0.00131	0.00342	CcSEcCtD
Ruxolitinib—Haemorrhage—Pamidronate—osteoporosis	0.00131	0.00342	CcSEcCtD
Ruxolitinib—Urinary tract infection—Zoledronate—osteoporosis	0.00129	0.00339	CcSEcCtD
Ruxolitinib—Infestation NOS—Conjugated Estrogens—osteoporosis	0.00128	0.00336	CcSEcCtD
Ruxolitinib—Infestation—Conjugated Estrogens—osteoporosis	0.00128	0.00336	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Estropipate—osteoporosis	0.00128	0.00336	CcSEcCtD
Ruxolitinib—Haematuria—Zoledronate—osteoporosis	0.00127	0.00332	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.00124	0.00325	CcSEcCtD
Ruxolitinib—Infection—Estropipate—osteoporosis	0.00123	0.00322	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.00123	0.00322	CcSEcCtD
Ruxolitinib—Malnutrition—Ethinyl Estradiol—osteoporosis	0.00123	0.00322	CcSEcCtD
Ruxolitinib—Nervous system disorder—Estropipate—osteoporosis	0.00121	0.00318	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Conjugated Estrogens—osteoporosis	0.00121	0.00317	CcSEcCtD
Ruxolitinib—Infection—Alendronate—osteoporosis	0.00121	0.00317	CcSEcCtD
Ruxolitinib—Skin disorder—Estropipate—osteoporosis	0.0012	0.00315	CcSEcCtD
Ruxolitinib—Malnutrition—Risedronate—osteoporosis	0.0012	0.00314	CcSEcCtD
Ruxolitinib—Infection—Raloxifene—osteoporosis	0.00119	0.00312	CcSEcCtD
Ruxolitinib—Flatulence—Risedronate—osteoporosis	0.00118	0.00309	CcSEcCtD
Ruxolitinib—Infection—Ibandronate—osteoporosis	0.00118	0.00309	CcSEcCtD
Ruxolitinib—Nervous system disorder—Raloxifene—osteoporosis	0.00117	0.00308	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Estradiol—osteoporosis	0.00117	0.00307	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Raloxifene—osteoporosis	0.00117	0.00307	CcSEcCtD
Ruxolitinib—Skin disorder—Raloxifene—osteoporosis	0.00116	0.00305	CcSEcCtD
Ruxolitinib—Nervous system disorder—Ibandronate—osteoporosis	0.00116	0.00305	CcSEcCtD
Ruxolitinib—Skin disorder—Ibandronate—osteoporosis	0.00115	0.00302	CcSEcCtD
Ruxolitinib—Malnutrition—Pamidronate—osteoporosis	0.00114	0.00298	CcSEcCtD
Ruxolitinib—Skin disorder—Calcitriol—osteoporosis	0.00113	0.00295	CcSEcCtD
Ruxolitinib—Anaemia—Risedronate—osteoporosis	0.00111	0.0029	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Estropipate—osteoporosis	0.00107	0.0028	CcSEcCtD
Ruxolitinib—Fatigue—Estropipate—osteoporosis	0.00107	0.00279	CcSEcCtD
Ruxolitinib—Anaemia—Pamidronate—osteoporosis	0.00105	0.00276	CcSEcCtD
Ruxolitinib—Weight increased—Estradiol—osteoporosis	0.00105	0.00274	CcSEcCtD
Ruxolitinib—Weight decreased—Estradiol—osteoporosis	0.00104	0.00272	CcSEcCtD
Ruxolitinib—Malnutrition—Zoledronate—osteoporosis	0.00104	0.00272	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.00104	0.00272	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Raloxifene—osteoporosis	0.00103	0.00271	CcSEcCtD
Ruxolitinib—Infestation NOS—Estradiol—osteoporosis	0.00102	0.00269	CcSEcCtD
Ruxolitinib—Infestation—Estradiol—osteoporosis	0.00102	0.00269	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Ibandronate—osteoporosis	0.00102	0.00268	CcSEcCtD
Ruxolitinib—Fatigue—Ibandronate—osteoporosis	0.00102	0.00268	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.00101	0.00265	CcSEcCtD
Ruxolitinib—Pruritus—Etidronic acid—osteoporosis	0.00101	0.00265	CcSEcCtD
Ruxolitinib—Malnutrition—Conjugated Estrogens—osteoporosis	0.001	0.00262	CcSEcCtD
Ruxolitinib—Urinary tract infection—Estradiol—osteoporosis	0.000996	0.00261	CcSEcCtD
Ruxolitinib—Infection—Ethinyl Estradiol—osteoporosis	0.000995	0.00261	CcSEcCtD
Ruxolitinib—Flatulence—Conjugated Estrogens—osteoporosis	0.000986	0.00258	CcSEcCtD
Ruxolitinib—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000982	0.00257	CcSEcCtD
Ruxolitinib—Haematuria—Estradiol—osteoporosis	0.000977	0.00256	CcSEcCtD
Ruxolitinib—Body temperature increased—Estropipate—osteoporosis	0.000977	0.00256	CcSEcCtD
Ruxolitinib—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000973	0.00255	CcSEcCtD
Ruxolitinib—Infection—Risedronate—osteoporosis	0.00097	0.00254	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Estradiol—osteoporosis	0.000969	0.00254	CcSEcCtD
Ruxolitinib—Epistaxis—Estradiol—osteoporosis	0.000967	0.00253	CcSEcCtD
Ruxolitinib—Body temperature increased—Alendronate—osteoporosis	0.000962	0.00252	CcSEcCtD
Ruxolitinib—Anaemia—Zoledronate—osteoporosis	0.000961	0.00252	CcSEcCtD
Ruxolitinib—Nervous system disorder—Risedronate—osteoporosis	0.000958	0.00251	CcSEcCtD
Ruxolitinib—Skin disorder—Risedronate—osteoporosis	0.000949	0.00249	CcSEcCtD
Ruxolitinib—Body temperature increased—Raloxifene—osteoporosis	0.000946	0.00248	CcSEcCtD
Ruxolitinib—Body temperature increased—Ibandronate—osteoporosis	0.000937	0.00246	CcSEcCtD
Ruxolitinib—Haemoglobin—Estradiol—osteoporosis	0.000925	0.00242	CcSEcCtD
Ruxolitinib—Infection—Pamidronate—osteoporosis	0.000923	0.00242	CcSEcCtD
Ruxolitinib—Haemorrhage—Estradiol—osteoporosis	0.00092	0.00241	CcSEcCtD
Ruxolitinib—Body temperature increased—Calcitriol—osteoporosis	0.000917	0.0024	CcSEcCtD
Ruxolitinib—Nervous system disorder—Pamidronate—osteoporosis	0.000911	0.00239	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Pamidronate—osteoporosis	0.000909	0.00238	CcSEcCtD
Ruxolitinib—Headache—Etidronic acid—osteoporosis	0.000895	0.00235	CcSEcCtD
Ruxolitinib—Asthenia—Estropipate—osteoporosis	0.000887	0.00232	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000879	0.0023	CcSEcCtD
Ruxolitinib—Pruritus—Estropipate—osteoporosis	0.000874	0.00229	CcSEcCtD
Ruxolitinib—Asthenia—Alendronate—osteoporosis	0.000873	0.00229	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000865	0.00227	CcSEcCtD
Ruxolitinib—Fatigue—Ethinyl Estradiol—osteoporosis	0.000864	0.00226	CcSEcCtD
Ruxolitinib—Pruritus—Alendronate—osteoporosis	0.000861	0.00226	CcSEcCtD
Ruxolitinib—Asthenia—Ibandronate—osteoporosis	0.00085	0.00223	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000846	0.00222	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Risedronate—osteoporosis	0.000843	0.00221	CcSEcCtD
Ruxolitinib—Infection—Zoledronate—osteoporosis	0.000843	0.00221	CcSEcCtD
Ruxolitinib—Fatigue—Risedronate—osteoporosis	0.000842	0.00221	CcSEcCtD
Ruxolitinib—Pruritus—Ibandronate—osteoporosis	0.000839	0.0022	CcSEcCtD
Ruxolitinib—Asthenia—Calcitriol—osteoporosis	0.000832	0.00218	CcSEcCtD
Ruxolitinib—Nervous system disorder—Zoledronate—osteoporosis	0.000832	0.00218	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Zoledronate—osteoporosis	0.00083	0.00218	CcSEcCtD
Ruxolitinib—Skin disorder—Zoledronate—osteoporosis	0.000824	0.00216	CcSEcCtD
Ruxolitinib—Pruritus—Calcitriol—osteoporosis	0.000821	0.00215	CcSEcCtD
Ruxolitinib—Dizziness—Estropipate—osteoporosis	0.000817	0.00214	CcSEcCtD
Ruxolitinib—Infection—Conjugated Estrogens—osteoporosis	0.000811	0.00213	CcSEcCtD
Ruxolitinib—Dizziness—Alendronate—osteoporosis	0.000805	0.00211	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000802	0.0021	CcSEcCtD
Ruxolitinib—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000801	0.0021	CcSEcCtD
Ruxolitinib—Malnutrition—Estradiol—osteoporosis	0.000801	0.0021	CcSEcCtD
Ruxolitinib—Fatigue—Pamidronate—osteoporosis	0.000801	0.0021	CcSEcCtD
Ruxolitinib—Skin disorder—Conjugated Estrogens—osteoporosis	0.000793	0.00208	CcSEcCtD
Ruxolitinib—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000792	0.00208	CcSEcCtD
Ruxolitinib—Dizziness—Raloxifene—osteoporosis	0.000792	0.00207	CcSEcCtD
Ruxolitinib—Flatulence—Estradiol—osteoporosis	0.000789	0.00207	CcSEcCtD
Ruxolitinib—Dizziness—Ibandronate—osteoporosis	0.000784	0.00205	CcSEcCtD
Ruxolitinib—Headache—Estropipate—osteoporosis	0.000774	0.00203	CcSEcCtD
Ruxolitinib—Body temperature increased—Risedronate—osteoporosis	0.000772	0.00202	CcSEcCtD
Ruxolitinib—Headache—Alendronate—osteoporosis	0.000763	0.002	CcSEcCtD
Ruxolitinib—Headache—Raloxifene—osteoporosis	0.00075	0.00197	CcSEcCtD
Ruxolitinib—Headache—Ibandronate—osteoporosis	0.000743	0.00195	CcSEcCtD
Ruxolitinib—Body temperature increased—Pamidronate—osteoporosis	0.000734	0.00192	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000732	0.00192	CcSEcCtD
Ruxolitinib—Fatigue—Zoledronate—osteoporosis	0.000731	0.00192	CcSEcCtD
Ruxolitinib—Headache—Calcitriol—osteoporosis	0.000727	0.0019	CcSEcCtD
Ruxolitinib—Asthenia—Ethinyl Estradiol—osteoporosis	0.000719	0.00188	CcSEcCtD
Ruxolitinib—Pruritus—Ethinyl Estradiol—osteoporosis	0.000709	0.00186	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000705	0.00185	CcSEcCtD
Ruxolitinib—Fatigue—Conjugated Estrogens—osteoporosis	0.000704	0.00185	CcSEcCtD
Ruxolitinib—Asthenia—Risedronate—osteoporosis	0.000701	0.00184	CcSEcCtD
Ruxolitinib—Pruritus—Risedronate—osteoporosis	0.000691	0.00181	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000677	0.00177	CcSEcCtD
Ruxolitinib—Body temperature increased—Zoledronate—osteoporosis	0.000671	0.00176	CcSEcCtD
Ruxolitinib—Asthenia—Pamidronate—osteoporosis	0.000666	0.00175	CcSEcCtD
Ruxolitinib—Dizziness—Ethinyl Estradiol—osteoporosis	0.000663	0.00174	CcSEcCtD
Ruxolitinib—Pruritus—Pamidronate—osteoporosis	0.000657	0.00172	CcSEcCtD
Ruxolitinib—Infection—Estradiol—osteoporosis	0.000649	0.0017	CcSEcCtD
Ruxolitinib—Dizziness—Risedronate—osteoporosis	0.000646	0.00169	CcSEcCtD
Ruxolitinib—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000646	0.00169	CcSEcCtD
Ruxolitinib—Nervous system disorder—Estradiol—osteoporosis	0.000641	0.00168	CcSEcCtD
Ruxolitinib—Skin disorder—Estradiol—osteoporosis	0.000635	0.00166	CcSEcCtD
Ruxolitinib—Headache—Ethinyl Estradiol—osteoporosis	0.000628	0.00164	CcSEcCtD
Ruxolitinib—Dizziness—Pamidronate—osteoporosis	0.000614	0.00161	CcSEcCtD
Ruxolitinib—Headache—Risedronate—osteoporosis	0.000612	0.0016	CcSEcCtD
Ruxolitinib—Asthenia—Zoledronate—osteoporosis	0.000609	0.00159	CcSEcCtD
Ruxolitinib—Pruritus—Zoledronate—osteoporosis	0.0006	0.00157	CcSEcCtD
Ruxolitinib—Asthenia—Conjugated Estrogens—osteoporosis	0.000586	0.00154	CcSEcCtD
Ruxolitinib—Headache—Pamidronate—osteoporosis	0.000582	0.00152	CcSEcCtD
Ruxolitinib—Pruritus—Conjugated Estrogens—osteoporosis	0.000578	0.00151	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Estradiol—osteoporosis	0.000564	0.00148	CcSEcCtD
Ruxolitinib—Fatigue—Estradiol—osteoporosis	0.000564	0.00148	CcSEcCtD
Ruxolitinib—Dizziness—Zoledronate—osteoporosis	0.000561	0.00147	CcSEcCtD
Ruxolitinib—Dizziness—Conjugated Estrogens—osteoporosis	0.00054	0.00142	CcSEcCtD
Ruxolitinib—Headache—Zoledronate—osteoporosis	0.000531	0.00139	CcSEcCtD
Ruxolitinib—Body temperature increased—Estradiol—osteoporosis	0.000517	0.00135	CcSEcCtD
Ruxolitinib—Headache—Conjugated Estrogens—osteoporosis	0.000512	0.00134	CcSEcCtD
Ruxolitinib—Asthenia—Estradiol—osteoporosis	0.000469	0.00123	CcSEcCtD
Ruxolitinib—Pruritus—Estradiol—osteoporosis	0.000462	0.00121	CcSEcCtD
Ruxolitinib—Dizziness—Estradiol—osteoporosis	0.000432	0.00113	CcSEcCtD
Ruxolitinib—Headache—Estradiol—osteoporosis	0.000409	0.00107	CcSEcCtD
Ruxolitinib—JAK3—Signaling Pathways—SPP1—osteoporosis	2.24e-05	4.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CALCA—osteoporosis	2.24e-05	4.33e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FGB—osteoporosis	2.23e-05	4.31e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—IL6—osteoporosis	2.23e-05	4.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PSMA2—osteoporosis	2.22e-05	4.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PSMA5—osteoporosis	2.22e-05	4.29e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AGER—osteoporosis	2.22e-05	4.28e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6R—osteoporosis	2.21e-05	4.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—P4HB—osteoporosis	2.21e-05	4.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ADCY5—osteoporosis	2.21e-05	4.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KL—osteoporosis	2.2e-05	4.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—IL6—osteoporosis	2.19e-05	4.23e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IRS1—osteoporosis	2.18e-05	4.2e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—IL6—osteoporosis	2.16e-05	4.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—IL6—osteoporosis	2.16e-05	4.17e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PSMA2—osteoporosis	2.15e-05	4.16e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PSMA5—osteoporosis	2.15e-05	4.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTH—osteoporosis	2.15e-05	4.15e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—IL6—osteoporosis	2.14e-05	4.13e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CALCA—osteoporosis	2.13e-05	4.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6R—osteoporosis	2.13e-05	4.11e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL1B—osteoporosis	2.12e-05	4.1e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—MYC—osteoporosis	2.12e-05	4.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RAP1A—osteoporosis	2.11e-05	4.08e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TGFB1—osteoporosis	2.11e-05	4.08e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—ADCY5—osteoporosis	2.1e-05	4.06e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IRS1—osteoporosis	2.1e-05	4.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CNR2—osteoporosis	2.1e-05	4.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	2.09e-05	4.03e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—ADCY5—osteoporosis	2.08e-05	4.02e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL1B—osteoporosis	2.07e-05	4.01e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CALCA—osteoporosis	2.07e-05	4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NFATC1—osteoporosis	2.06e-05	3.98e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IRS2—osteoporosis	2.05e-05	3.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—DKK1—osteoporosis	2.05e-05	3.95e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6R—osteoporosis	2.04e-05	3.95e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KL—osteoporosis	2.03e-05	3.93e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IRS2—osteoporosis	2.03e-05	3.92e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—POMC—osteoporosis	2.02e-05	3.9e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CALCA—osteoporosis	2.01e-05	3.88e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ADCY5—osteoporosis	1.99e-05	3.85e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IRS2—osteoporosis	1.99e-05	3.85e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—MYC—osteoporosis	1.99e-05	3.84e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—LEP—osteoporosis	1.98e-05	3.83e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TGFB1—osteoporosis	1.98e-05	3.83e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—IL6—osteoporosis	1.98e-05	3.83e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6R—osteoporosis	1.97e-05	3.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—WNT1—osteoporosis	1.97e-05	3.81e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ADCY5—osteoporosis	1.96e-05	3.79e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL1B—osteoporosis	1.96e-05	3.78e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IGF1—osteoporosis	1.94e-05	3.75e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KL—osteoporosis	1.94e-05	3.74e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MTHFR—osteoporosis	1.93e-05	3.74e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IRS2—osteoporosis	1.93e-05	3.73e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—IL6—osteoporosis	1.93e-05	3.73e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—SPP1—osteoporosis	1.93e-05	3.73e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—IL6—osteoporosis	1.92e-05	3.7e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGA—osteoporosis	1.92e-05	3.7e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—SPP1—osteoporosis	1.9e-05	3.67e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—ESR1—osteoporosis	1.9e-05	3.66e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—ADCY5—osteoporosis	1.89e-05	3.65e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—IL6—osteoporosis	1.89e-05	3.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KL—osteoporosis	1.88e-05	3.63e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—TGFB1—osteoporosis	1.88e-05	3.63e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IRS2—osteoporosis	1.84e-05	3.55e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—POMC—osteoporosis	1.83e-05	3.54e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KL—osteoporosis	1.82e-05	3.52e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—MYC—osteoporosis	1.8e-05	3.48e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TGFB1—osteoporosis	1.79e-05	3.47e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IRS1—osteoporosis	1.79e-05	3.46e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6R—osteoporosis	1.79e-05	3.45e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BMP2—osteoporosis	1.78e-05	3.44e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTHLH—osteoporosis	1.78e-05	3.44e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IRS1—osteoporosis	1.77e-05	3.42e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—TNF—osteoporosis	1.75e-05	3.39e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IRS2—osteoporosis	1.74e-05	3.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGB—osteoporosis	1.74e-05	3.37e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IRS1—osteoporosis	1.74e-05	3.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AGER—osteoporosis	1.73e-05	3.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ADCY5—osteoporosis	1.73e-05	3.33e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IRS2—osteoporosis	1.72e-05	3.32e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—LEP—osteoporosis	1.71e-05	3.3e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—POMC—osteoporosis	1.71e-05	3.29e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—IL6—osteoporosis	1.69e-05	3.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL6—osteoporosis	1.69e-05	3.26e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IRS1—osteoporosis	1.69e-05	3.26e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL1B—osteoporosis	1.68e-05	3.25e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PSMA5—osteoporosis	1.68e-05	3.25e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PSMA2—osteoporosis	1.68e-05	3.25e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6R—osteoporosis	1.68e-05	3.25e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—LEP—osteoporosis	1.68e-05	3.24e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—MYC—osteoporosis	1.67e-05	3.22e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—TGFB1—osteoporosis	1.66e-05	3.21e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6R—osteoporosis	1.66e-05	3.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—IL6—osteoporosis	1.66e-05	3.21e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IGF1—osteoporosis	1.64e-05	3.17e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6R—osteoporosis	1.63e-05	3.16e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ESR1—osteoporosis	1.63e-05	3.15e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—POMC—osteoporosis	1.62e-05	3.13e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IRS1—osteoporosis	1.61e-05	3.1e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ESR1—osteoporosis	1.6e-05	3.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ADCY5—osteoporosis	1.59e-05	3.08e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—IL6—osteoporosis	1.59e-05	3.07e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6R—osteoporosis	1.58e-05	3.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CALCA—osteoporosis	1.57e-05	3.03e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—FDPS—osteoporosis	1.53e-05	2.96e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PKM—osteoporosis	1.53e-05	2.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—POMC—osteoporosis	1.53e-05	2.96e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IRS1—osteoporosis	1.52e-05	2.94e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ADCY5—osteoporosis	1.52e-05	2.93e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IRS2—osteoporosis	1.51e-05	2.92e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6R—osteoporosis	1.51e-05	2.91e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—IL6—osteoporosis	1.5e-05	2.9e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IRS1—osteoporosis	1.5e-05	2.89e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IL6—osteoporosis	1.5e-05	2.89e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—IL6—osteoporosis	1.49e-05	2.87e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ADCY5—osteoporosis	1.47e-05	2.84e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SPP1—osteoporosis	1.47e-05	2.83e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—POMC—osteoporosis	1.47e-05	2.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MTHFR—osteoporosis	1.47e-05	2.83e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PGLS—osteoporosis	1.45e-05	2.8e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPD2—osteoporosis	1.45e-05	2.8e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—POMC—osteoporosis	1.44e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6R—osteoporosis	1.43e-05	2.76e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ADCY5—osteoporosis	1.43e-05	2.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KL—osteoporosis	1.42e-05	2.75e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SPP1—osteoporosis	1.42e-05	2.75e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TGFB1—osteoporosis	1.42e-05	2.75e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—IL6—osteoporosis	1.41e-05	2.73e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IGF1—osteoporosis	1.41e-05	2.73e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6R—osteoporosis	1.41e-05	2.72e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TGFB1—osteoporosis	1.4e-05	2.7e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IRS2—osteoporosis	1.39e-05	2.69e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—POMC—osteoporosis	1.39e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IGF1—osteoporosis	1.39e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SPP1—osteoporosis	1.38e-05	2.67e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL6—osteoporosis	1.36e-05	2.62e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6R—osteoporosis	1.36e-05	2.62e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IL6—osteoporosis	1.35e-05	2.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TNF—osteoporosis	1.33e-05	2.57e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IRS2—osteoporosis	1.33e-05	2.56e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ATIC—osteoporosis	1.33e-05	2.56e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PNP—osteoporosis	1.33e-05	2.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IRS1—osteoporosis	1.32e-05	2.55e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—LEP—osteoporosis	1.3e-05	2.51e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IRS2—osteoporosis	1.29e-05	2.49e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—IL6—osteoporosis	1.29e-05	2.49e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL1B—osteoporosis	1.28e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—LEP—osteoporosis	1.26e-05	2.44e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—IL6—osteoporosis	1.25e-05	2.42e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—IL6—osteoporosis	1.25e-05	2.42e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—IL6—osteoporosis	1.25e-05	2.41e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IRS2—osteoporosis	1.25e-05	2.41e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL6—osteoporosis	1.24e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL1B—osteoporosis	1.24e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ESR1—osteoporosis	1.24e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6R—osteoporosis	1.24e-05	2.39e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—LEP—osteoporosis	1.22e-05	2.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IRS1—osteoporosis	1.22e-05	2.35e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL6—osteoporosis	1.21e-05	2.35e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—IL6—osteoporosis	1.21e-05	2.34e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MYC—osteoporosis	1.21e-05	2.34e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—TGFB1—osteoporosis	1.21e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL1B—osteoporosis	1.21e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ESR1—osteoporosis	1.2e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MYC—osteoporosis	1.17e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ESR1—osteoporosis	1.17e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TGFB1—osteoporosis	1.17e-05	2.25e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IRS1—osteoporosis	1.16e-05	2.24e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL6—osteoporosis	1.15e-05	2.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6R—osteoporosis	1.14e-05	2.21e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CA2—osteoporosis	1.13e-05	2.18e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—OXCT1—osteoporosis	1.13e-05	2.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IRS1—osteoporosis	1.12e-05	2.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ADCY5—osteoporosis	1.12e-05	2.16e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—POMC—osteoporosis	1.12e-05	2.16e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MGLL—osteoporosis	1.1e-05	2.12e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IRS1—osteoporosis	1.09e-05	2.11e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6R—osteoporosis	1.09e-05	2.1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—POMC—osteoporosis	1.08e-05	2.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SPP1—osteoporosis	1.08e-05	2.09e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL6—osteoporosis	1.08e-05	2.08e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IGF1—osteoporosis	1.07e-05	2.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—IL6—osteoporosis	1.07e-05	2.07e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL6—osteoporosis	1.06e-05	2.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6R—osteoporosis	1.06e-05	2.04e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—POMC—osteoporosis	1.05e-05	2.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF1—osteoporosis	1.04e-05	2.01e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6R—osteoporosis	1.02e-05	1.98e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF1—osteoporosis	1.01e-05	1.95e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—osteoporosis	9.86e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MYC—osteoporosis	9.86e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TGFB1—osteoporosis	9.83e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IRS2—osteoporosis	9.76e-06	1.89e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—LEP—osteoporosis	9.55e-06	1.85e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—osteoporosis	9.47e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1B—osteoporosis	9.42e-06	1.82e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—IDH2—osteoporosis	9.35e-06	1.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ESR1—osteoporosis	9.12e-06	1.76e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—osteoporosis	9.1e-06	1.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—osteoporosis	8.94e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TGFB1—osteoporosis	8.92e-06	1.72e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP27A1—osteoporosis	8.79e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—osteoporosis	8.78e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ACP5—osteoporosis	8.55e-06	1.65e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IRS1—osteoporosis	8.52e-06	1.65e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—osteoporosis	8.48e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TGFB1—osteoporosis	8.46e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—osteoporosis	8.34e-06	1.61e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TGFB1—osteoporosis	8.32e-06	1.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—POMC—osteoporosis	8.21e-06	1.59e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6R—osteoporosis	8.01e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—osteoporosis	7.97e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TPI1—osteoporosis	7.95e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1—osteoporosis	7.89e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—osteoporosis	7.5e-06	1.45e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—P4HB—osteoporosis	7.47e-06	1.44e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—osteoporosis	7.41e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GAPDH—osteoporosis	7.33e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—osteoporosis	7.28e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—RAP1A—osteoporosis	7.14e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—osteoporosis	7.06e-06	1.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—osteoporosis	6.77e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFB1—osteoporosis	6.76e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—osteoporosis	6.72e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—osteoporosis	6.45e-06	1.25e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFB1—osteoporosis	6.43e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—osteoporosis	6.37e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—osteoporosis	6.27e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—osteoporosis	6.26e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFB1—osteoporosis	6.24e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—osteoporosis	6.07e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFB1—osteoporosis	6.06e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—osteoporosis	6.04e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ENO1—osteoporosis	5.77e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PSMA2—osteoporosis	5.69e-06	1.1e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PSMA5—osteoporosis	5.69e-06	1.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—osteoporosis	5.52e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—osteoporosis	5.09e-06	9.84e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—osteoporosis	4.85e-06	9.36e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—osteoporosis	4.74e-06	9.17e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFB1—osteoporosis	4.73e-06	9.14e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—osteoporosis	4.71e-06	9.09e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP19A1—osteoporosis	4.62e-06	8.92e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—osteoporosis	4.56e-06	8.82e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ADCY5—osteoporosis	3.77e-06	7.29e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPX1—osteoporosis	3.76e-06	7.26e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—osteoporosis	3.57e-06	6.89e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTHFR—osteoporosis	3.47e-06	6.7e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—POMC—osteoporosis	2.77e-06	5.36e-06	CbGpPWpGaD
